Other Dermatologicals
| Drug | Dosage | Remarks |
|---|---|---|
| Ivermectin | Classical Scabies Children ≥15 kg and adults: 200 mcg/kg PO single dose Repeat dose after 1-2 weeks Crusted Scabies In combination with topical scabicide Children ≥15 kg and adults: 200 mcg/kg PO given in sequence below depending on severity: 3 doses: Days 1, 2 and 8 5 doses: Days 1, 2, 8, 9 and 15 7 doses: Days 1, 2, 8, 9, 15, 22 and 29 |
Adverse Reactions
|
Topical Antifungals & Antiparasites
| Drug | Available Strength | Dosage | Remarks |
|---|---|---|---|
| Benzyl benzoate | 25% emulsion | Apply and leave on for 24 hours then wash off May repeat within 5 days or apply 3x at 12-hour intervals followed by bathing 12 hours after last application |
Adverse Reactions
|
| Crotamiton | 10% cream, lotion | Apply 12-24 hourly x 3-5 days Antipruritic: Apply 8-12 hourly |
Adverse Reactions
|
| Malathion | 0.5% topical emulsion | Apply and leave on for 8-12 hours then wash off May repeat after 7 days |
Adverse Reactions
|
| Lindane (Benzene hexachloride) |
1% lotion | Children ≥10 years old and adults: Apply a thin layer and leave on for 8-12 hours then wash off |
Adverse Reactions
|
| Permethrin | 5% cream, lotion | Classical scabies: Apply and leave on for 8-14 hours then wash off Repeat after 7 days Crusted scabies: Apply and leave on for 8-14 hours then wash off x 7 days |
Adverse Reactions
|
| Sulfur | 2% bar soap 5-10% cream, ointment |
Apply and leave on for 24 hours then wash off x 3-5 days |
Adverse Reactions
|
Disclaimer
All dosage recommendations are for non-pregnant and non-breastfeeding women, and non-elderly adults with normal renal and hepatic function unless otherwise stated.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.
